Dispensing Codivir

Phase 2Small molecule

CCode Pharma

Dispensing Codivir is one of 46 small molecule programs targeting HIV infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

326 competitors in HIV Infection

#DrugCompanyPhaseTrials

Leukine

Sanofi

Phase 3

2 2

Hivid

CConrado Roberto Hoffmann Filho

Phase 3

9 3

Intron a

Merck & Co.

Phase 3

1 4

Sunlenca

Gilead

Phase 3

1 5

Praluent

Regeneron

Phase 3

1 6

PEG-Intron

Megace

Betaseron

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3 10

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HIV infection1 trial

Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants

Recruiting·CCode Pharma·Phase 2·NCT06676410·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dispensing Codivir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dispensing Codivir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dispensing Codivir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Code Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCode Pharma

Dispensing Codivir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HIV infection1 trial

References

Drug Info

Quick Facts

Related News